Study of Combined Use of Directional Atherectomy and Local Drug Delivery With Balloon Catheter System in the Treatment of Femoropopliteal Occlusive Disease
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 主要终点
- patency rate
研究概览
简要总结
This study will evaluate the effectiveness and safety of directional atherectomy plus local drug delivery using balloon catheter system in the treatment of femoropopliteal occlusive disease. Patients of femoropopliteal occlusive disease will randomly receive directional atherectomy plus local drug delivery using balloon catheter system and dilation using drug-coated balloon. Their clinical outcomes (e.g. 12-month late lumen loss rate, 1-year patency rate of target vessel) in 1 year after the treatment will be compared.
详细描述
Femoropopliteal occlusive disease is a common type of peripheral arterial disease. Endovascular treatment has been the first-line treatment of femoropopliteal occlusive disease. However, the in-stent re-stenosis has been a major limitation of well long-term patency rate after stent implantation. The chronic inflammation induced by stenting could be a main reason of re-stenosis. Then the concept "leave nothing behind" is proposed, and some novel treatment methods and devices, such as paclitaxel-coated balloon dilation, directional atherectomy, are developed. Directional atherectomy can effectively remove the atherosclerosis plaque but leave the inflammatory reaction along the atherectomy route. Here, we propose the hypothesis that using local drug delivery with balloon system can relieve the inflammation induced by atherectomy. Therefore, 40 patients of femoropopliteal occlusive disease will be randomly allocated into the group "directional atherectomy+local drug delivery with balloon system" or "drug-coated balloon only". The 1-year patency rate, incidence of complications, imaging parameters will be compared between groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
only the doctor know the group the patient goes into
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age of 18-80 years old
- •patients of femoropopliteal occlusive disease (Rutherford 2-4)
- •length of lesion ≤ 20cm
- •have signed the informed consent
排除标准
- •serum Cr > 150 umol/L
- •patients with acute thrombosis
- •received endovascular treatment for femoropopliteal disease in recent 6 months
- •less than 1 run-off vessel
- •allergic to aspirin, heparin, clopidogrel, paclitaxel, contrast medium
- •pregnancy and lactation
- •relatively easy bleeding
- •malignancy or irreversible organ failure
结局指标
主要结局
patency rate
时间窗: 12 months
the rate of patency of target vessel
late lumen loss rate
时间窗: 12 months
the rate of late lumen loss of target vessel
次要结局
- incidence of complications(12 months)
- adverse events(12 months)
- Rutherford level(12 months)
- re-stenosis rate(12 months)
- ABI(12 months)
- main amputation(12 months)
- MLD(12 months)
- clinical outcomes(12 months)
